For thyroid cancer patients with confirmed metastases, multiple doses of radioactive iodine (average 11.1 GBq total) can control tumor growth in most cases (96% had no progression), though only about 72% remained free of disease worsening after five years, and many eventually stopped responding to treatment.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether radioiodine oncolytic therapy improves progression-free survival compared to tyrosine kinase inhibitors or observation in patients with metastatic, iodine-avid differentiated thyroid cancer.
A systematic review and meta-analysis of all randomized trials comparing radioiodine oncolytic therapy (cumulative dose ≥10 GBq) to first-line tyrosine kinase inhibitors (e.g., lenvatinib, sorafenib) or observation in patients with metastatic, iodine-avid DTC, with primary outcome of progression-free survival and secondary outcomes of toxicity and quality of life.
Whether radioiodine oncolytic therapy improves progression-free survival compared to observation in patients with metastatic, iodine-avid differentiated thyroid cancer.
A multicenter, randomized trial of 300 patients with metastatic, iodine-avid DTC and measurable disease, randomized to receive radioiodine oncolytic therapy (cumulative 11.1 GBq) or observation, with primary endpoint of progression-free survival by RECIST 1.1 criteria at 5 years, and mandatory serial Tg and imaging every 6 months.
Whether radioiodine oncolytic therapy independently predicts progression-free survival after adjusting for tumor burden, metastatic site, and Tg kinetics.
A prospective cohort study of 500 patients with metastatic DTC and confirmed iodine avidity, treated with radioiodine oncolytic therapy, with multivariate analysis controlling for number of metastatic sites, Tg doubling time, age, and prior treatments to determine independent predictors of progression-free survival.
Whether patients who developed progression after radioiodine oncolytic therapy were less likely to have received adequate cumulative dosing or had higher baseline Tg levels.
A case-control study comparing 100 patients with progression after radioiodine oncolytic therapy to 200 matched controls without progression, assessing cumulative radioiodine dose, baseline Tg, number of metastases, and time to refractoriness.
The proportion of patients with metastatic DTC who achieve structural disease control after a single course of radioiodine oncolytic therapy at a single time point.
A cross-sectional analysis of 250 patients with metastatic DTC who received radioiodine oncolytic therapy, assessing structural response by RECIST 1.1 criteria at 6 months post-treatment, stratified by cumulative dose and number of lesions.